知镜 Cognispect · 医学文献与研究工作台

Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis.

Choi HS, Yoon HY, Park SY, Lee J, Kang JY, Cho JY, Jung SS, Choi WI, Korean Interstitial Lung Disease Study Group.
Tuberculosis and respiratory diseases · 2026-08-26 · PMID 42642341

文献摘要

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia marked by declining lung function, severe dyspnea, and a poor prognosis. Antifibrotic agents have improved outcomes in patients with IPF, but diagnosing the disease, monitoring its course, and managing it over the long term remain challenging. Since the publication of the first Korean clinical practice guideline for interstitial lung disease in 2018, research has advanced substantially and has reshaped the clinical management of IPF. This updated guideline draws on evidence published over the past 5 years and covers the epidemiology, pathogenesis, risk factors, clinical manifestations, diagnosis, treatment, comorbidities, prognosis, and acute exacerbations of IPF. Expert consensus was also used to formulate key clinical questions, and systematic reviews and meta-analyses were then performed to reassess how antifibrotic agents affect lung function decline, mortality, and acute exacerbations in patients with IPF. This guideline aims to standardize the clinical management of IPF, improve diagnostic accuracy, and encourage the appropriate use of available treatments. It is intended for physicians, other healthcare professionals who care for patients with IPF, and healthcare policymakers in Korea.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。